Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and
SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First
North Premier in 2016 and has attracted a highly-experienced management team.

Read more

Acarix grundades 2009 och sedan 2010 har danska riskkapitalföretagen Sunstone Life Science Ventures
och Seed Capital finansierat utvecklingen av bolaget och stöttat det mot en introduktion på
marknaden. Acarix noterades på Nasdaq First North Premier 2016 och har en mycket erfaren
ledningsgrupp.

Read more

CADScor®System launched in key markets: ”In 2017, we achieved historic milestones in Acarix – most noticeably the receipt of our first commercial order for CADScor®System in June and thus a confirmation of the commercialization program being on track.”

Read more

CADScor®System lanserat på viktiga marknader: ”Under 2017 uppnådde vi historiska milstolpar på Acarix: den viktigaste var vår första kommersiella order på ett CADScor®System i juni, vilket var en bekräftelse på att kommersialiseringsprogrammet löpte enligt plan. ”

Read more

Acarix AB (publ) (“Acarix”), developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of the company’s current CFO, Christian Lindholm as interim Chief Executive Officer. Lindholm replaces CEO Søren Rysholt Christiansen who announced his resignation on November 6th, 2017.

Read more